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Ramesh Singh1, Radhika Pochampally1, Kounosuke Watabe2, Zhaohui Lu3* and Yin-Yuan Mo4*Abstract
Introduction: Exosomes are 30-100 nm membrane vesicles of endocytic origin, mediating diverse biological functions
including tumor cell invasion, cell-cell communication and antigen presentation through transfer of proteins, mRNAs
and microRNAs. Recent evidence suggests that microRNAs can be released through ceramide-dependent secretory
machinery regulated by neutral sphingomyelinase 2 (nSMase2) enzyme encoded by the smpd3 gene that triggers
exosome secretion. However, whether exosome-mediated microRNA transfer plays any role in cell invasion remains
poorly understood. Thus, the aim of this study was to identify the exosomal microRNAs involved in breast cancer
invasion.
Methods: The expression level of endogenous and exosomal miRNAs were examined by real time PCR and the
expression level of target proteins were detected by western blot. Scanning electron and confocal microscopy were
used to characterize exosomes and to study its uptake and transfer. Luciferase reporter plasmids and its mutant were
used to confirm direct targeting. Furthermore, the functional significance of exosomal miR-10b was estimated by
invasion assay.
Results: In this study, we demonstrate that microRNA carrying exosomes can be transferred among different cell lines
through direct uptake. miR-10b is highly expressed in metastatic breast cancer MDA-MB-231 cells as compared to
non-metastatic breast cancer cells or non-malignant breast cells; it is actively secreted into medium via exosomes. In
particular, nSMase2 or ceramide promotes the exosome-mediated miR-10b secretion whereas ceramide inhibitor
suppresses this secretion. Moreover, upon uptake, miR-10b can suppress the protein level of its target genes such as
HOXD10 and KLF4, indicating its functional significance. Finally, treatment with exosomes derived from MDA-MB-231
cells could induce the invasion ability of non-malignant HMLE cells.
Conclusion: Together, our results suggest that a set of specific microRNAs may play an important role in modulating
tumor microenvironment through exosomes. Thus, a better understanding of this process may aid in the development
of novel therapeutic agents.
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The biological functions in higher organisms are executed
by intercellular communication through complex assem-
blies of cells, the action of which must be highly coordi-
nated. This cell-cell communication is also a vital aspect
for development of various diseases including cancer. It
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unless otherwise stated.communication is achieved by autocrine, paracrine or
direct cell to cell contact. There is increasing evidence
suggesting that cells may also communicate via other
mechanisms in addition to these known methods, includ-
ing exchange of cellular fragments, membranes or special-
ized organelles like microvesicles which until recently has
been regarded as cellular debris. The two major forms of
vesicles are ectosomes and exosomes. Ectosomes emerge
from cellular membrane while the exosomes are of endo-
somal origin [1].
Exosomes are nanovesicles with diameter ranging from
30-120 nm; they are derived from endocytic compartmentstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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Exosome biogenesis is a complex and controlled process
that begins with the inward budding of cellular membrane
to form an early endosome. After the endosome formation,
cytoplasmic content is internalized into small vesicles, i.e.,
exosomes. When exosomes are present inside the endo-
some, the endosome forms a multivesicular body (MVB)
which later on fuses with the cellular membrane to release
the exosomes [2]. Exosome cargo includes a variety of bio-
molecules ranging from lipids, proteins to nucleic acids that
include mRNA, microRNA and DNA. In addition to their
size and morphology, exosomes can be identified by virtue
of their unique protein and lipid composition. This includes
raft-lipids such as cholesterol, sphingolipids, ceramide and
glycerophospolipids with long and saturated fatty-acyl
chains. Due to their endosomal origin, exosomes from
different cell types contains common proteins such as
Rab GTPases, Annexins, flotillin, Alix, TSG101, hsp70 and
hsp90, integrins and tetraspanins (CD63, CD9, CD81 and
CD82). Some of these proteins can be used as marker pro-
teins to identify and characterize exosomes. These exoso-
mal marker proteins includes Alix, flotillin, TSG101 and
CD63 [3]. Recent independent studies have confirmed the
idea that these cell-derived vesicles carry and deliver micro-
RNAs to recipient cells in vitro [4-6]. Also, the presence of
circulating microRNAs in the blood of cancer patients has
raised the possibility that they may serve as a novel diag-
nostic marker [7]. For example, microRNA profiling on
serum from breast cancer patients found that seven micro-
RNAs (miR-10b, miR-21, miR-125b, miR-145, miR-155
miR-191 and miR-382) had different expression patterns in
serum of breast cancer patients compared to healthy con-
trols [8]. In particular, the overexpression of miR-21, miR-
10b, and miR-19a can be utilized as serum biomarkers for
aggressive breast cancer and inflammatory breast cancer as
they are associated with the acquisition of malignant char-
acteristics like increased tumor cell proliferation, migration,
invasion, dissemination, and metastasis [9]. In another case
involving 89 patients with primary breast cancer (n =59)
and metastatic disease (n =30), and 29 healthy women,
breast cancer-associated miR-10b, miR-34a, miR-141 and
miR-155 were elevated in the blood of breast cancer
patients and are associated with tumor progression [10].
Although, the role of exosomal miRNAs in cancer progres-
sion and metastasis is still poorly understood, emerging evi-
dence suggests cancer-secreted exosomal microRNAs are
emerging as mediators of cancer progression and metasta-
sis. For example, Zhou et al., demonstrated that miR-105 is
a potent regulator of migration through targeting the tight
junction protein ZO-1 and is characteristically expressed
and secreted by metastatic breast cancer cells [11]. Over-
expression of miR-105 in nonmetastatic breast cancer cells
can induce metastasis, whereas inhibition of miR-105 in
highly metastatic tumors has the opposite effect [11].Another study showed that exosomal miR-210 which is se-
creted by metastatic cancer cells, can enhance angiogenesis
after its uptake by endothelial cells through suppression of
specific target genes [12]. Also, exosomal miRNAs can dir-
ectly interact with proteins like Toll-like receptors (TLRs)
to drive an immune response and to activate nuclear
factor-kB (NF-kB) pathway that can help in tumor gener-
ation, development and immune surveillance escape pro-
moting chronic inflammation [13]. These findings indicate
that the horizontal transfer of exosomal microRNAs from
cancer cells to non-malignant cells can modify the micro-
enviromental niche for their own advantage.
Although it becomes evident now that microRNAs can
be carried in exosomes and transported in the circulating
system, it remains largely unknown whether these micro-
RNAs have any function. In this study, we present evidence
that exosomes can be transferred among different cell lines
through direct uptake and in process delivers the micro-
RNAs to the recipient cells. Upon uptake, microRNAs can
still reduce the protein level of its target genes, indicating
its functional significance. We found that miR-10b derived
from MDA-MB-231 cells can be transferred to non-
malignant HMLE cells via exosomes. Moreover, this trans-
ferred miR-10b can promote invasion in HMLE cells in
part by targeting a known miR-10b target, HOXD10 [14].
Materials and methods
Reagents
HMLE cells were a generous gift from Dr. Robert Weinberg
(The Massachusetts Institute of Technology). Primary anti-
bodies were obtained as follows: monoclonal anti-β-actin
and anti-HOXD10 from Sigma-Aldrich (Allentown, PA);
anti-KLF4 from Cell Signaling Technology (Beverly, MA).
Secondary antibodies conjugated with IRDye 800CW or
IRDye 680 were purchased from LI-COR Biosciences
(Lincoln, NE, USA). Luciferase reporters, pMIR-D10UTR
for HOXD10 3′UTR (#19117) and HOXD10 mut 3′ UTR
(#19116), were purchased from Addgene (Cambridge MA).
PCR primers and FAM-miR-10b were purchased from IDT
(Coralville, IA).
Cell culture
The human MCF-7 and MDA-MB-231 cells were obtained
from ATCC (Manassas, VA, USA) and cultured in RPMI-
1640 with 10% FBS (Sigma, St. Louis, MO). MCF-10A and
HMLE cells were cultured in DMEM/F12K supplemented
with growth factor hEGF, hydrocortisone, insulin and 100
units of penicillin/ml and 100 mg of streptomycin/ml.
HEK-293T cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) (Cambrex) supplemented with
10% FBS. All media contained 2 mM glutamine, 100 units
of penicillin/ml and 100 mg of streptomycin/ml. Cells were
incubated at 37°C and supplemented with 5% CO2 in a
humidified chamber. For experiments, cells were grown in
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added to the cell culture medium was depleted of
exosomes by ultracentrifugation at 120,000 × g overnight
(16 h) at 4°C, followed by passing it through 0.2 micron
filter prior to use.
Exosome isolation and labeling
Cells for exosome isolation from culture medium were
maintained in respective medium with exosome-free
FBS which was prepared by centrifugations to remove
existing exosomes. Exosomes were isolated from cell cul-
ture medium collected after 48 h by differential centrifu-
gations as described by Raposo and colleagues with a
small modification [15]. Briefly, the collected culture
mixture was centrifuged at 300 × g for 10 min, followed
by 2000 × g for 20 min. The supernatant was further
filtered by a 0.22-μM filter (Millipore). The obtained
medium was centrifugated at 100,000 × g for 60 min at
4°C to pellet exosomes. The supernatant was discarded
without disturbing the pellet which was then washed
with a large volume of PBS, ultracentrifugated and fi-
nally resuspended again in PBS. Purified exosomes were
labeled with PKH26 red fluorescent labeling kit (Sigma)
as per manufacturer’s protocol.
Expression vectors
The high fidelity enzyme Phusion was used to amplify re-
spective DNA fragments by PCR to make these constructs.
To construct the GFP-CD63 fusion, we first amplified
copGFP with primers copGFP-R1-5.1 and copGFP-CD63-
3.1; CD63 with primers copGFP-CD63-5.1 and CD63-
pCDH-PU-Not1-3.1. These two fragments were then
cloned into pCDH-PU (SBI) at EcoR I and Not I site by
cold fusion method (SBI). To clone miR-10b, a genomic
DNA fragment (~500 bp) carrying miR-10b precursor was
amplified from human genomic DNA with miR-10b-5.1
and miR-10b-3.1. The PCR fragment was first cloned into
PCR8 (Life Technology) and then this fragment was mi-
grated into pCDH-CMV-copGFP (SBI). SMPD3 expres-
sion vector was cloned by the same PCR amplification
approach using primers SMPD3-R1-5.1 and SMPD3-
Not1-3.1 and then cloned into pCDH-CMV-myc-EF1-
GFP-PU at EcoR I and Not I site by cold fusion method.
For cloning the KLF4 plus UTR, we used primers KLF4-
Myc-R1-5.1 and KLF4-UTR-Not1-3.1, and then cloned
into the pCDH-PU (SBI) at EcoR I and Not I restriction
site. The sequences of all PCR products were verified by
DNA sequencing.
Transfection
Cells were transfected with miR-10b mimic using RNA-
fectin reagent or with plasmid DNA using DNAfectin
(both from Applied Biological Materials, Vancouver,
Canada) following the manufacturer’s protocol.Confocal microscopy
Confocal microscopy was carried out by using the Leica
confocal microscope at the imaging facility of Southern
Illinois University School of Medicine or Nikon C1 con-
focal microscope at Imaging Core at Center for Psychi-
atric Neuroscience of UMMC.
Scanning electron microscopy (SEM)
An aliquot of exosome suspension was loaded on to a
carbon-coated electron microscopy grid. The sample
was fixed with 2% glutaraldehyde and 2% paraformalde-
hyde in 0.1 M sodium cacodylate buffer at pH 7.3. After
two washes in distilled H2O, the samples were stained
with 2% methylamine tungstate for 45 s and air-dried.
Finally the samples were observed in a Zeiss scanning
electron microscope.
RNA preparation and RT-PCR
For RT-PCR, we isolated total RNA using Trizol reagent
(Invitrogen, Carlsbad, CA) as per the manufacturer’s
protocol and used 0.5 μg RNA to synthesize cDNA by
SuperScriptase III (Invitrogen) with random primers.
Finally, the resultant cDNA was used for PCR reactions.
PCR annealing temperature varied depending on the
primers used. To detect miR-10b, we used the polymer-
ase A method, followed by SYBR Green qPCR as de-
scribed previously [16]. RNU1 and 5s RNA were used as
an internal control.
Western blotting
Cells were harvested and protein was extracted from cells
as previously described [17]. The protein concentration
was determined using a protein assay kit (Bio-Rad,
Hercules, CA, USA) and samples were separated in SDS
polyacrylamide gels, with various concentrations depend-
ing on the molecular weight of the protein under inves-
tigation. After probing with a primary antibody, the
membrane was incubated with a secondary antibody la-
beled with either IRDye 800CW or IRDye 680. Finally,
signal intensity was determined using the Odyssey Infrared
Imaging System (LI-COR Biosciences, Lincoln, NE, USA).
Invasion assay
To determine whether miR-10b can confer invasion abil-
ity through exosome transfer, we overexpressed miR-10b
in MDA-MB-231 cells and then isolated exosomes from
the conditioned medium. The isolated exosomes were
mixed with HMLE cells and incubated for 24 h before
subject to invasion assays. Specifically, matrigel cham-
bers (BD Biosciences) were used to determine the inva-
siveness per the manufacturer’s protocol as described
previously [18]. In brief, cells were harvested, resus-
pended in serum-free medium, and then transferred to
the hydrated Matrigel chambers (∼25,000 cells per well).
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medium with 10% FBS in the bottom chambers before
examination. The cells on the upper surface were
scraped and washed away, whereas the invaded cells
on the lower surface were fixed and stained with
0.05% crystal violet for 2 h. Finally, invaded cells were
counted under a microscope and the relative number
was calculated.
Luciferase reporter assay
Luciferase assays were carried out in HMLE cells. Cells
were transfected with firefly luciferase reporters (pMIR-
D10UTR for HOXD10 3′UTR and HOXD10 mut 3′
UTR) (400 ng) and 2 ng of the pRL-SV40 renilla lucifer-
ase construct in 12-well plates. Then they were incu-
bated with appropriate exosomes for 24 h and finally
harvested and lysed for luciferase assays. Luciferase
assays were performed using a luciferase assay kit
(Promega) according to the manufacturer’s protocol.
Renilla luciferase was used for normalization.
Preparation of the lentiviral particles and infection
Lentiviral packaging was carried out in HEK-293T cells
using a packaging system from System Biosciences as
per the manufacturer’s protocol, as described previously
[19]. For a large scale preparation the viral particles were
concentrated by centrifugation. The final titer was at
least 1 × 108. For infection, exponentially growing cells
were mixed with viral particles in the presence of poly-
brene (0.8 mg/ml) in a six-well plate at a multiplicity of
infection of 1-3.


















Data are presented as mean ± SE; the Student’s t-test was
used for assessing the difference between individual groups
and P ≤ 0.05 was considered statistically significant.Results
Characterization of exosomes released from cancer cells
and their transfer from donor to recipient cells
Exosomes can be actively released from a variety of
cell types including cancer cells. To determine whether
microRNA-carrying exosomes can be released from breast
cancer cells, we incubated three cell lines, i.e., MCF-10A,
MCF-7 and MDA-MB-231, in exosome-free medium made
from exosome-free FBS. The exosomes in the conditioned
media were isolated by a serial centrifugations and filtration.
The harvested exosomes were then resuspended in PBS or
other agents depending upon further use [20]. To determine
the relative purity of isolated exosomes and their morph-
ology, the exosome pellets were resuspended in PBS and
then examined by scanning electron microscopy (SEM).
Shown in Figure 1A were the exosomes isolated from
MDA-MB-231 cells with a uniformly cup-shaped mor-
phology; their size was within the characteristic diameter
range of 40-120 nm. To further determine the nature of the
isolated exosomes, we used the exosome-specific marker
CD63 which has been used to provide a quantification of
the exosomes present in cell culture supernatants [21]. As
shown in Figure 1B, CD63 was not detected in whole cell
lysate but were found in abundance in the isolated exosomal
fraction. These results confirmed that the vesicles isolated
from the conditional media were the exosomes based on
their size and presence of marker protein, CD63.
To examine whether the secreted exosomes can be
taken up by recipient cells, we used two pronged ap-
proaches. In the first approach, we cloned CD63 along
with GFP as a fusion protein in a lentiviral vector and then
generated stable cell lines expressing CD63-GFP fusion.
The distribution of CD63-GFP was mainly in speckle like
structures (Figure 1C), very different from that of GFP
alone which was distributed uniformly in the entire cell.
Exosomes were then isolated from the HEK 293T cell line
stably over expressing the CD63-GFP fusion protein. After
addition of the isolated CD63-GFP tagged exosomes to
MCF-10A cells and incubation for 24 h, we examined
them under a confocal microscope. We found that almost
all of these cells were GFP positive with a similar speckle
like structures (Figure 1D). In the second approach, the
isolated exosomes from MDA-MB-231 cells were labeled
with PKH26 dye (red), washed thoroughly and then added
to MCF-7 and HEK-293T cells. The uptake of the labeled
exosomes by recipient cells was visualized under confocal
microscope. Again, almost all recipient cells revealed red
signal (Figure 1E). These results suggest that the uptake of
exosomes by these cells is every efficient.
Quantitative RT-PCR profiling for intracellular and
extracellular microRNAs
Having demonstrated that exosomes are released from





























Figure 1 Characterization of exosome transfer. A, Electron micrograph of exosomes isolated from MDA-MB-231 conditioned medium, revealing
the typical morphology and size (30-100 nm). B, Western blot showing presence of CD63 protein in exosome fraction from the same MDA-MB-231
conditioned medium. C, HEK-293T cells expressing CD63-GFP fusion protein compared to GFP alone. D, Cellular uptake of exosomes isolated from
HEK-293T cells expressing the CD63-GFP fusion protein by MCF-10A cells. Image was captured 24 h after addition of exosomes to the culture. E,
Intercellular trafficking of exosomes among different cell lines by isolated exosomes labeled with PKH26 dye. Shown here are for uptake in MCF-7 and
HEK-293T cell lines. Images were taken 24 h after exosome addition by confocal microscope.
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via exosomes. We chose metastatic MDA-MB-231 and
non-malignant HMLE cells for comparison. We profiled
the cancer-related microRNAs secreted in the conditioned
media as well as the endogenous level in these two cell
lines by qRT-PCR (Additional file 1: Table S1 and S2).
Among a total of 144 cancer-related microRNAs, the en-
dogenous miR-10b (i.e., from inside the cell) was remark-
ably and most highly expressed in MDA-MB-231 cells
whereas its expression was extremely low in HMLE cells,Table 1 Top 5 intracellular miRNAs overexpressed in
MDA-MB-231 cells as compared to HMLE cells
S.no miRNA Fold expression (SD)
1 miR-10b 13.21 ± 2.14
2 miR-218 12.68 ± 2.04
3 miR-10a 9.53 ± 2.09
4 miR-99a 9.09 ± 1.07
5 miR-142-3p 9.04 ± 0.58indicating that high expression of miR-10b is a distinct
feature of microRNA profile of MDA-MB-231 cells. Im-
portantly, similar expression pattern was observed in the
extracellular (i.e., exosomal) fraction for miR-10b, indicat-
ing that miR-10b can be actively secreted by MDA-MB-
231 cells but little was detected in HMLE conditioned
medium. Other top five intracellular and extracellular
microRNAs whose expression was higher in MDA-MB-
231 cells as compared to HMLE cells were listed in
Tables 1 and 2. Since miR-10b has significantly highTable 2 Top 5 extracellular miRNAs overexpressed in
MDA-MB-231 cells as compared to HMLE
S.no miRNA Fold expression (SD)
1 miR-10b 5.02 ± 0.68
2 miR-32 5.00 ± 4
3 miR-138 4.29 ± 0.04
4 miR-7e 4.13 ± 2.73
5 miR-106b 2.92 ± 0.57
Singh et al. Molecular Cancer 2014, 13:256 Page 6 of 11
http://www.molecular-cancer.com/content/13/1/256expression both at intracellular and extracellular level in
MDA-MB-231 cells as compared to HMLE cells and it
has been shown to plays a vital role in breast cancer inva-
sion and metastasis [14], we focused on miR-10b in the
following experiments.
Next, we examined the intracellular and extracellular
level of miR-10b in different breast cancer cells ranging
from epithelial to metastatic by real time PCR. This
includes MCF-10A and MCF-7 cell lines in addition to
HMLE and MDA-MB-231 cells. The results indicate that
the level of miR-10b is highest both at endogenous and
secretory level in metastatic MDA-MB-231 cells as
compared to epithelial like HMLE or MCF-10A as well
as non-metastatic MCF-7 cells (Figure 2A and B).
Secretion of miR-10b is regulated in a ceramide-
dependent manner
There have been various studies on the biogenesis and
release of exosomes. For example, Trajkovic et al., re-
ported that release of exosomes is independent of the
endosomal sorting complex (ESCRT) machinery and is
regulated by the sphingolipid ceramide [22]. Further, it
has been shown that the secretion of microRNAs is con-
trolled by neutral sphingomyelinase 2 (nSMase2), which
is known as a rate-limiting enzyme of ceramide biosyn-
thesis [23]. To determine whether ceramide biosynthesis
regulates exosomal miR-10b secretion in breast cancer
cells, we cloned the smpd3 gene coding for nSMase2 in
a lentiviral vector. qRT-PCR analysis revealed that the
level of secreted miR-10b was significantly higher in
both MCF-7 and MDA-MB-231 cells overexpressing
smpd3 than in vector control cells (Figure 3A and B). To
further confirm the role of ceramide on miR-10b release,
MDA-MB-231 cells were treated with 2 μM ceramide for
48 h. We detected an elevated level of secreted miR-10b


















Figure 2 Upregulation of miR-10 in MDA-MB-231 cells. Detection of di
among HMLE, MCF-10A, MCF-7 and MDA-MB-231 cell, as determined by qsecretion of this microRNA. In contrast, when MDA-
MB-231 cells were treated with a known ceramide in-
hibitor, GW4869 at 5 μM concentration for 48 h, there
was a significant inhibition in the miR-10b level as com-
pared to vehicle control (Figure 3D). Collectively, these
results support the notion that secretion of miR-10b is
regulated in a ceramide-dependent manner.
Transfer of miR-10b from donor cells to the recipient cells
through exosomes
To determine whether released microRNAs such as miR-
10b can be taken up by various types of cells, we isolated
exosomes from MDA-MB-231 cells and then incubated
them with HMLE cells. The uptake of miR-10b by HMLE
cells was determined by qRT-PCR after exosome treat-
ment. We found a 5-fold increase in the endogenous level
of miR-10b in HMLE cells treated with exosomes derived
from MDA-MB-231 cells as compared to control. In
addition, to visualize the transport of extracellular miR-
10b from MDA-MB-231 cells into HMLE cells, MDA-
MB-231 cells were transfected with FAM labeled miR-10b
and co-cultured with HMLE cells, using transwell. FAM-
miR-10b transfected MDA-MB-231 cells were seeded on
the transwell membrane whereas HMLE cells were seeded
at the bottom well so that they were not directly con-
tacted. We were able to detect the FAM-miR-10b green
signal in the cytoplasm of HMLE cells by confocal micros-
copy 24 h after co-culture (Figure 4B). To further confirm
that the transferred miR-10b was derived from exosomal
microRNA, we isolated the exosomes from culture
medium of MDA-MB-231 cells transfected with FAM-
labeled miR-10b. The isolated exosomes were then added
to HMLE cells. Again, the miR-10b signal was detected by
confocal microscopy in the cytoplasm of HMLE cells 24 h
later (Figure 4C) and the signal intensity was similar to































Figure 3 Regulation of exosomal miR-10b secretin by ceramide biosynthesis pathway. A, Detection of miR-10b from conditioned medium
of MCF-7 cells stably expressing smpd3 and vector control by qRT-PCR. B, Detection of miR-10b from conditioned medium of MDA-MB-231 cells
stably expressing smpd3 and vector control by qRT-PCR. C, Secretion of miR-10b is enhanced by the treatment with ceramide in MDA-MB-231
cells. D, Suppression of miR-10b secretion by ceramide biosynthesis inhibitor (GW4869) in MDA-MB-231 cells.
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MDA-MB-231 cells can be transferred into HMLE cells
and that the horizontal transfer of microRNAs occurs
through exosomes among various types of cells.
Exosomal miR-10b is functional inside the recipient cells
and can induce invasion ability in HMLE cells
Having demonstrated that miR-10b can be transferred
through exosomes from one cell to another, we next inves-
tigated whether miR-10b can still remain functional inside
the recipient cell. It has been reported that the miR-10b
can induce tumor invasion and initiate metastasis in breast
cancer by targeting HOXD10 [14] and promotes migra-
tion and invasion through direct binding with 3′-UTR of
KLF4 in human esophageal cancer cells [24]. To test the
functionality of the exosomal miR-10b in recipient cells,
we cloned miR-10b in lentiviral vector and generated cells
stably expressing miR-10b in MDA-MB-231. We next
checked the endogenous and secretory level of miR-10b
by real time PCR which confirmed the overexpression of
miR-10b by over 15 folds inside the cell and more im-
portantly, the secretory level of miR-10b increased by
more than 40 folds when compared to the vector control
(Additional file 1: Figure S1). For functional assay experi-
ments we used the exosomes isolated from these two
stable cells (vector and miR-10b) as they significantly dif-
fer in their miR-10b level. Enhanced miR-10b secretion in
MDA-MB-231 stable cell line is in consistent with apreviously published report that overexpression of micro-
RNA inside the cell increases the extracellular secretion
[23].
It has been reported that miR-10b overexpression does
not cause degradation of HOXD10 mRNA, but it reduces
the HOXD10 protein level, suggesting a translational
repression mechanism. This silencing action depends on
single miR-10b cognate binding site within the 3′-UTR re-
gion of HOXD10 gene as a mutant with four nucleotide
substitution fails to reduce the activity of a luciferase re-
porter system [14]. To determine that exosomal miR-10b
can have a similar effect on the luciferase activity, we
performed luciferase assays with the wild type human
HOXD10 3′-UTR; the mutant HOXD10 3′-UTR that
has a substitution of 4 nucleotides within the miR-10b
binding site, from TCGTAATGCAGGGTA to TCGTAA
TGCACCCAA as a control. These two constructs were
introduced into HMLE cells along with renilla luciferase
construct (for normalization purpose). The transfected
cells were then treated with miR-10b enriched exosomes
or the control exosomes. The miR-10 enriched exosomes
could reduce the activity of luciferase reporter gene in wild
type 3′-UTR reporter but not in the mutant 3′-UTR re-
porter as compared to control exosomes (Figure 5A).
To demonstrate the suppression of the endogenous
HOXD10 by exosomal miR-10b, exosomes were collected
from culture medium of MDA-MB-231 cell line derived
from the stably overexpressing miR-10b and the vector
Figure 4 Uptake of miR-10b by HMLE cells. A, Exosomal miR-10b was isolated from MDA-MB-231 cells and then added to HMLE cell culture.
The control received the exosome-free medium. B, Detection of FAM-miR-10b in the exosome-treated HMLE cells. HMLE cells were co-cultured
with MDA-MB-231 cells that had been transfected with FAM-labeled-miR-10b using transwell without direct contact. Twenty-four hours after
co-culture, HMLE cells were fixed in 4% paraformaldehyde, and analyzed by fluorescent microscope. Green signals indicate FAM-miR-10b while
nuclear counterstaining was performed using propidium iodide (PI). C, The FAM-miR-10b carrying exosomes were first isolated from the same
MDA-MB-231 cells that had been transfected with FAM-labeled-miR-10b and then were added to HMLE culture, fixed and visualized by
microscopy. FAM-miR-10b signals (green) were spotted around the nucleus similar to what was seen in B.
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exosome treatment, the protein level of HOXD10 was de-
termined by western blot which indicates down regulation
of this protein in cells treated with miR-10b enriched
exosomes as compared to vector control (Figure 5B).
Another known target of miR-10b is KLF4 [24]. Since
HMLE cells express little KLF4, we cloned KLF4 coding
region plus its 3′-UTR and the protein was tagged with
Myc at the N-terminus. This construct was then transi-
ently transfected into HEK-293T cells. Again, the miR-10b
enriched exosomes along with control exosomes were
added to HEK-293T cells with KLF4 construct. After 24 h
of transfection, there was an obvious decrease in the KLF4
protein level in cells treated with miR-10b enriched exo-
somes as compared to vector control (Figure 5C). Thisprovides additional evidence that secreted miR-10b can
still remain functional after uptake in the recipient cells.
Finally, given that suppression of HOXD10 increases cell
invasion [14], we determined whether miR-10b carried on
exosomes can induce invasion ability of HMLE cells by a
transwell invasion assay. After 24 h incubation of HMLE
cells with the enriched exosomes derived from miR-10b
and vector control, there was a significant increased inva-
sion ability as compared to the vector control (Figure 5D).
For example, invasion ability for miR-10b exosomes was
over a 6-fold higher than for vector exosomes (Figure 5E),
suggesting that exosomal miR-10b remains functional
inside the recipient HMLE cells after uptake and can
induce the invasion ability by silencing miR-10b targets
such as HOXD10 involved in cell invasion.
Figure 5 Exosomal miR-10b promotes cell invasion by targeting HOXD10. A, Exosomal miR-10b (E-miR-10b) suppresses the luciferase
activity of the luciferase reporter carrying HOXD10 3′-UTR. Both wild-type (UTR-WT) or mutant (UTR-mut) reporters were introduced into HMLE
cells by transfection and then incubated with the miR-10b-enriched exosomes or control. B, Suppression of HOXD10 protein in HMLE cells by
exosomal miR-10b. Protein extract was prepared 48 h after addition of exosomal miR1-10b to the HMLE culture. C, Suppression of KLF4 in
HEK-293T cells transfected with in KLF4 plus 3′-UTR. D, Suppression of cell invasion in HMLE cells by exosomal miR-10b. E, Quantitative analysis of
data obtained from D.
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Accumulating evidence indicates that microRNAs play a
key role in tumor progression and metastasis and they can
be stably present in the circulating system. Thus, these
microRNAs have been explored as cancer biomarkers
[25,26]. Furthermore, a specific set of exosomal micro-
RNAs may modulate the tumor microenvironment [27].
However, it remains largely unknown as to whether and
how exosomal microRNAs play a role in cancer develop-
ment and progression. This study identifies miR-10b as an
exosomal microRNA that promotes cell invasion in HMLE
cells by targeting HOXD10, suggesting that invasive tumor
cells may use exosomal microRNAs as a means for their
advance.
We first confirmed that exosome secretion from tumor
cells is an active process which is regulated by the ceramide
biosynthesis pathway [22]. In consistent with the previous
reports [22,23], we showed that overexpression of smpd3
gene or exogenous ceramide increases the amount of exo-
somal microRNAs; on the other hand, treatment withGW4869 results in a reduced secretion of exosomal micro-
RNAs. We also showed that overexpression of miR-10b in
MDA-MB-231 cells leads to an increase of exosomal miR-
10b in the conditioned medium, suggesting that the
intracellular level of microRNAs affects the amount of
corresponding exosomal microRNAs.
When exosomes are released to the medium, they can
be taken up by recipient cells which can be the same type
or a different type of cells. Thus, we isolated exosomes
from either HEK-29T or MDA-MB-231 cells and then ex-
amined their uptake by MCF-10A, HEK-239T or MCF-7
cells. Overall, the uptake seems very efficient. For example,
using the GFP-CD63 fusion reporter, we found that all of
MCF-10A cells reveal GFP signal after incubation with
exsomes isolated from HEK-293T cell transfected with
GFP-CD63 (Figure 1D). Similarly, the uptake is also high
in HEK-239T or MCF-7 cells when isolated exosomes
were stained with PKH26 dye (Figure 1D and E). These re-
sults suggest that microRNA transfer via exosomes among
different types of cells occur readily.
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can have a significant impact in a variety of physiological
and pathological conditions. Yang et al., showed that
exosomal miR-223, secreted from macrophages can pro-
mote the invasion of breast cancer cells via Mef2c-β-
catenin pathway [28]. Exosomal microRNAs derived
from K562 cells release the miR-17-92 cluster which tar-
get integrin α5 in HUVECs upon uptake, and enhance
endothelial cell migration and tube formation [29]. Of
interest, miR-21 and miR-29a secreted from tumors can
bind as ligands to toll-like receptors in immune cells
and trigger prometastatic inflammatory responses that
may promote tumor growth and metastasis [13]. Since
cancer cells secrete the microRNAs through exosomes
into the circulatory system, this feature can be utilized
as a new approach for the detection of various malig-
nancies. For instance, serum miR-141 levels have been
reported to help distinguish patients suffering from
prostate cancer from healthy controls [30]. Our study
provides evidence that there is a significant difference in
the level of exosomal microRNAs secreted by different
breast cancer cell lines. For instance, the level of exoso-
mal miR-10b is much higher in metastatic breast cancer
MDA-MB-231 cells than non-metastatic MCF-7 cells.
Importantly, this exosomal miR-10b which is actively
secreted by MDA-MB-231 cells can be taken up by non-
malignant epithelial breast cells to promote their cell
invasion.
Various studies have demonstrated that several micro-
RNAs are involved in breast cancer progression and me-
tastasis. These include miR-9 [31], miR-10b [14], miR-21
[32], miR-29a [33], miR-155 [34], miR-200a [35], miR-
374a [36] and several other microRNAs. Metastasis is a
multistep process which involves epithelial to mesenchy-
mal transition (EMT), intravasation, transport via circula-
tion, extravasation, mesenchymal to epithelial transition
(MET), micrometastasis and finally metastasis. One of the
major requirement of this complex and multistep process
of metastasis is cell to cell communication. The most
common mode of cell-cell communication involves two
cells in direct contact with each other, communicating via
gap junctions. Other methods include paracrine signaling
where secretions from one cell have an effect only on cells
in the immediate area and endocrine signaling involving
hormones that are released into the circulatory system
which then reach to the target cell. Our result provides
evidence that exosomes are also one of the important
mediators of cell-cell communication.
In this regard, exosomal miR-10b derived from meta-
static MDA-MB-231 cells is capable of inducing invasion
ability upon uptake in non-invasive breast epithelial
HMLE cells. It is well known that breast tumors are very
heterogeneous, and the ability of tumor cells in the same
tumor to invade and progress can vary a lot. Our findingmay suggest that less invasive tumor cells can become
more invasive by obtaining exosomal microRNAs from
the invasive tumor cells in the tumor microenvironment.
If this is the case, it would be conceivable that tumor
cells can cooperate through exosome-mediated micro-
RNA transfer to advance in the hostile environment,
which supports the “game theory” of cancer evolution
proposed by Dr. Robert Axelrod [37].
In summary, our work provides another piece of evi-
dence that microRNAs can be transported through exo-
somes from among different cell types facilitating cell to
cell communication. Oncogenic microRNAs like miR-
10b, secreted by breast cancer cells, can influence the
adjacent and distant normal cells which can lead to out-
come in favor of tumor development and progression.
Based on these results we envision that targeting exoso-
mal microRNAs may provide an alternative approach for
breast cancer intervention.
Additional file
Additional file 1: Supplementary information.
Abbreviations
EMT: Mesenchymal transition; MVB: Multivesicular body; MET: Epithelial transition;
NSMase2: Neutral sphingomyelinase 2; SEM: Scanning electron microscopy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
RS carried out the experiments, and drafted the manuscript. RP, KW and ZL
contributed reagents and analysis tools. ZL and YM conceived and designed
the experiments and data analysis and preparation of manuscript. All authors
read and approved the final manuscript.
Acknowledgement
This work was supported by NIH grant R01 CA154989 (YM) and DoD Breast
Cancer Research Program BC085628 (YM). Confocal microscope at Center for
Psychiatric Neuroscience of UMMC is supported by grant GM103328.
Author details
1Department of Biochemistry and Cancer Institute, University of Mississippi
Medical Center, Jackson, MS, USA. 2Department of Microbiology and Cancer
Institute, University of Mississippi Medical Center, Jackson, MS, USA.
3Department of Endocrinology, PLA General Hospital, Beijing 100853, PR
China. 4Department of Pharmacology/Toxicology and Cancer Institute,
University of Mississippi Medical Center, Jackson, MS, USA.
Received: 31 May 2014 Accepted: 13 November 2014
Published: 26 November 2014
References
1. Lee TH, D’Asti E, Magnus N, Al-Nedawi K, Meehan B, Rak J: Microvesicles as
mediators of intercellular communication in cancer–the emerging science
of cellular ‘debris’. Semin Immunopathol 2011, 33:455–467.
2. Zomer A, Vendrig T, Hopmans ES, van Eijndhoven M, Middeldorp JM, Pegtel
DM: Exosomes: Fit to deliver small RNA. Commun Integr Biol 2010, 3:447–450.
3. Simons M, Raposo G: Exosomes–vesicular carriers for intercellular
communication. Curr Opin Cell Biol 2009, 21:575–581.
4. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO: Exosome-
mediated transfer of mRNAs and microRNAs is a novel mechanism of
genetic exchange between cells. Nat Cell Biol 2007, 9:654–659.
Singh et al. Molecular Cancer 2014, 13:256 Page 11 of 11
http://www.molecular-cancer.com/content/13/1/2565. Wang K, Zhang S, Weber J, Baxter D, Galas DJ: Export of microRNAs and
microRNA-protective protein by mammalian cells. Nucleic Acids Res 2010,
38:7248–7259.
6. Ohshima K, Inoue K, Fujiwara A, Hatakeyama K, Kanto K, Watanabe Y,
Muramatsu K, Fukuda Y, Ogura S, Yamaguchi K, Mochizuki T: Let-7
microRNA family is selectively secreted into the extracellular
environment via exosomes in a metastatic gastric cancer cell line. PLoS
One 2010, 5:e13247.
7. Kosaka N, Iguchi H, Ochiya T: Circulating microRNA in body fluid: a new
potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010,
101:2087–2092.
8. Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, Espino-Silva PK,
Santuario-Facio SK, Ruiz-Flores P, Rodriguez-Padilla C, Resendez-Perez D:
Serum circulating microRNA profiling for identification of potential
breast cancer biomarkers. Dis Markers 2013, 34:163–169.
9. Anfossi S, Giordano A, Gao H, Cohen EN, Tin S, Wu Q, Garza RJ, Debeb BG,
Alvarez RH, Valero V, Hortobagyi GN, Calin GA, Ueno NT, Woodward WA,
Reuben JM: High serum miR-19a levels are associated with inflammatory
breast cancer and are predictive of favorable clinical outcome in patients
with metastatic HER2+inflammatory breast cancer. PLoS One 2014,
9(1):e83113. doi: 10.1371/journal.pone.0083113.
10. Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H: Circulating
microRNAs as blood-based markers for patients with primary and
metastatic breast cancer. Breast Cancer Res 2010, 12:R90.
11. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A,
O’Connor ST, Chin AR, Yen Y, Wang Y, Marcusson EG, Chu P, Wu J, Wu X, Li
AX, Li Z, Gao H, Ren X, Boldin MP, Lin PC, Wang SE: Cancer-secreted
miR-105 destroys vascular endothelial barriers to promote metastasis.
Cancer Cell 2014, 25(4):501–515. doi: 10.1016/j.ccr.2014.03.007.
12. Kosaka N, Iguchi H, Hagiwara K, Yoshioka Y, Takeshita F, Ochiya T:
Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of
angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem 2013,
288:10849–10859.
13. Fabbri M, Paone A, Calore F, Galli R, Gaudio E, Santhanam R, Lovat F, Fadda P,
Mao C, Nuovo GJ, Zanesi N, Crawford M, Ozer GH, Wernicke D, Alder H,
Caligiuri MA, Nana-Sinkam P, Perrotti D, Croce CM: MicroRNAs bind to Toll-like
receptors to induce prometastatic inflammatory response. Proc Natl Acad Sci
U S A 2012, 109(31):E2110–E2116. doi: 10.1073/pnas.1209414109.
Epub 2012 Jul 2.
14. Ma L, Teruya-Feldstein J, Weinberg RA: Tumour invasion and metastasis
initiated by microRNA-10b in breast cancer. Nature 2007, 449:682–688.
15. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ,
Geuze HJ: B lymphocytes secrete antigen-presenting vesicles. J Exp Med
1996, 183:1161–1172.
16. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY: miR-21-mediated tumor growth.
Oncogene 2007, 26:2799–2803.
17. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, Elble R, Watabe K,
Mo YY: p53 represses c-Myc through induction of the tumor suppressor
miR-145. Proc Natl Acad Sci U S A 2009, 106:3207–3212.
18. Sachdeva M, Mo YY: MicroRNA-145 suppresses cell invasion and
metastasis by directly targeting mucin 1. Cancer Res 2010, 70:378–387.
19. Sachdeva M, Liu Q, Cao J, Lu Z, Mo YY: Negative regulation of miR-145 by
C/EBP-beta through the Akt pathway in cancer cells. Nucleic Acids Res
2012, 40:6683–6692.
20. Lässer C, Eldh M, Lötvall J: Isolation and characterization of RNA-
containing exosomes. J Vis Exp 2012, (59):e3037. doi: 10.3791/3037.
21. Logozzi M, De Milito A, Lugini L, Borghi M, Calabrò L, Spada M, Perdicchio
M, Marino ML, Federici C, Iessi E, Brambilla D, Venturi G, Lozupone F,
Santinami M, Huber V, Maio M, Rivoltini L, Fais S: High levels of exosomes
expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS
One 2009, 4(4):e5219. doi:10.1371/journal.pone.0005219. Epub 2009 Apr 17.
22. Trajkovic K, Hsu C, Chiantia S, Rajendran L, Wenzel D, Wieland F, Schwille P,
Brugger B, Simons M: Ceramide triggers budding of exosome vesicles
into multivesicular endosomes. Science 2008, 319:1244–1247.
23. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T:
Secretory mechanisms and intercellular transfer of microRNAs in living
cells. J Biol Chem 2010, 285:17442–17452.
24. Tian Y, Luo A, Cai Y, Su Q, Ding F, Chen H, Liu Z: MicroRNA-10b promotes
migration and invasion through KLF4 in human esophageal cancer cell
lines. J Biol Chem 2010, 285:7986–7994.25. Mo MH, Chen L, Fu Y, Wang W, Fu SW: Cell-free circulating miRNA
biomarkers in cancer. J Cancer Educ 2012, 3:432–448.
26. Di Leva G, Croce CM: miRNA profiling of cancer. Curr Opin Genet Dev 2013,
23:3–11.
27. Rana S, Malinowska K, Zoller M: Exosomal tumor microRNA modulates
premetastatic organ cells. Neoplasia 2013, 15:281–295.
28. Yang M, Chen J, Su F, Yu B, Su F, Lin L, Liu Y, Huang JD, Song E:
Microvesicles secreted by macrophages shuttle invasion-potentiating
microRNAs into breast cancer cells. Mol Cancer 2011, 10:117.
29. Umezu T, Ohyashiki K, Kuroda M, Ohyashiki JH: Leukemia cell to
endothelial cell communication via exosomal miRNAs. Oncogene 2013,
32:2747–2755.
30. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL,
Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW,
Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB,
Tewari M: Circulating microRNAs as stable blood-based markers for
cancer detection. Proc Natl Acad Sci U S A 2008, 105(30):10513–10518.
doi: 10.1073/pnas.0804549105. Epub 2008 Jul 28.
31. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, Teruya-Feldstein J,
Reinhardt F, Onder TT, Valastyan S, Westermann F, Speleman F, Vandesompele
J, Weinberg RA: miR-9, a MYC/MYCN-activated microRNA, regulates
E-cadherin and cancer metastasis. Nat Cell Biol 2010, 12(3):247–256.
doi:0.1038/ncb2024. Epub 2010 Feb 21.
32. Yan LX, Huang XF, Shao Q, Huang MY, Deng L, Wu QL, Zeng YX, Shao JY:
MicroRNA miR-21 overexpression in human breast cancer is associated
with advanced clinical stage, lymph node metastasis and patient poor
prognosis. RNA 2008, 14:2348–2360.
33. Gebeshuber CA, Zatloukal K, Martinez J: miR-29a suppresses tristetraprolin,
which is a regulator of epithelial polarity and metastasis. EMBO Rep 2009,
10:400–405.
34. Kong W, He L, Richards EJ, Challa S, Xu CX, Permuth-Wey J, Lancaster JM,
Coppola D, Sellers TA, Djeu JY, Cheng JQ: Upregulation of miRNA-155
promotes tumour angiogenesis by targeting VHL and is associated with
poor prognosis and triple-negative breast cancer. Oncogene 2014,
33:679–689.
35. Yu SJ, Hu JY, Kuang XY, Luo JM, Hou YF, Di GH, Wu J, Shen ZZ, Song HY,
Shao ZM: MicroRNA-200a promotes anoikis resistance and metastasis
by targeting YAP1 in human breast cancer. Clin Cancer Res 2013,
19:1389–1399.
36. Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan J, Wu J, Li M: MicroRNA-374a
activates Wnt/beta-catenin signaling to promote breast cancer
metastasis. J Clin Invest 2013, 123:566–579.
37. Axelrod R, Axelrod DE, Pienta KJ: Evolution of cooperation among tumor
cells. Proc Natl Acad Sci U S A 2006, 103:13474–13479.
doi:10.1186/1476-4598-13-256
Cite this article as: Singh et al.: Exosome-mediated transfer of miR-10b
promotes cell invasion in breast cancer. Molecular Cancer 2014 13:256.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
